Patent Assignment
Reel/Frame 016871/0736
Assignment of Assignor's Interest
Recorded: 2005-10-18
Pages: 32
Assignor
AMGEN SF, LLC
Executed: 2005-06-17
Assignee
AMGEN INC.
ONE AMGEN CENTER DR., THOUSAND OAKS, CALIFORNIA, 91320-1799
Covered Properties
(271)
Host Cell Factor, Nucleic Acids Encoding Hcf, and Methods of Use
Application:
07/989,842 →
Novel Eukaryotic Transcription Protein: Host Cell Factor
Patent:
5,453,362 →
Application:
08/046,585 →
Transcription Factor-Dna Binding Assay
Patent:
5,563,036 →
Application:
08/235,503 →
Epstein-Barr Virus Transcription Factor Binding Assay
Application:
08/246,977 →
Interleukin 4 Signal Transducers and Binding Assays
Application:
08/269,604 →
Nuclear Factors and Binding Assay
Application:
08/270,653 →
Interleukin 4 Signal Transducers
Patent:
5,591,825 →
Application:
08/276,099 →
High-Throughput Screening Assay for Inhibitors of Nucleic Acid Polymerases
Patent:
5,635,349 →
Application:
08/348,797 →
Interleukin-2 Signal Transducers and Binding Assays
Patent:
5,618,693 →
Application:
08/393,333 →
Herpes Simplex Virus Drug Screen
Patent:
5,585,239 →
Application:
08/393,703 →
Nuclear Factors and Binding Assay
Patent:
5,612,455 →
Application:
08/396,479 →
Human Signal Transducer and Binding Assays
Patent:
5,639,858 →
Application:
08/408,318 →
Tnf Receptor-Associated Intracellular Signaling Proteins and Methods of Use
Patent:
5,563,039 →
Application:
08/414,625 →
Interleukin-1 Receptor-Associated Protein Kinase and Assays
Application:
08/494,006 →
Inhibitors of Apoptosis
Application:
08/512,946 →
Rip: Novel Human Protein Involved in Tumor Necrosis Factor Signal Transduction, and Screening Assays
Application:
08/553,727 →
Transcriptional Promoter of the Murine Obesity Gene
Patent:
5,698,389 →
Application:
08/558,545 →
C-Iap 1 and C-Iap 2: Inhibitors of Apoptosis
Patent:
6,187,557 →
Application:
08/569,749 →
Interleukin-1 Receptor-Associated Protein Kinase and Assays
Patent:
5,654,397 →
Application:
08/587,889 →
Pentafluorobenzenesulfonamides and Analogs
Application:
08/605,431 →
High-Throughput Screening Assay for Inhibitors of Nucleic Acid Helicases
Patent:
5,705,344 →
Application:
08/616,046 →
Tumor Necrosis Factor Receptor Associated Factor 6 (TRAF6)
Patent:
5,710,013 →
Application:
08/639,237 →
Human Telomerase Rna Interacting Protein Gene
Patent:
5,747,317 →
Application:
08/676,967 →
Assays Using TRAF2-Associated Protein Kinase Polypeptides
Patent:
5,874,230 →
Application:
08/677,862 →
Kinase Assay
Patent:
5,759,787 →
Application:
08/702,970 →
Epstein-Barr Virus Transcription Factor Binding Assay
Patent:
5,679,525 →
Application:
08/704,398 →
Drug Screens for Regulators of the Expression of the Obese Gene
Patent:
5,780,258 →
Application:
08/707,408 →
Nucleic Acid Encoding an Interleukin 4 Signal Transducer
Patent:
5,710,266 →
Application:
08/781,890 →
Regulators of Apoptosis
Patent:
6,242,569 →
Application:
08/795,088 →
Ikb Kinases
Patent:
5,837,514 →
Application:
08/812,533 →
Nuclear Factors and Binding Assays
Patent:
5,708,158 →
Application:
08/818,823 →
STAT6 Deficient Transgenic Mice
Patent:
5,866,760 →
Application:
08/823,051 →
Nucleic Acid Encoding Human Signal Transducer and Activator of Transcription 4
Patent:
5,756,700 →
Application:
08/839,164 →
Regulators of UCP2 Gene Expression
Patent:
5,807,740 →
Application:
08/846,012 →
Cell-Based Drug Screens for Regulators of Gene Expression
Patent:
6,566,089 →
Application:
08/866,942 →
High Throughout Nucleic Acid Primase Assay
Application:
08/882,606 →
Ikk-Beta Proteins, Nucleic Acids and Methods
Application:
08/887,114 →
Ikk -a Proteins, Nucleic Acids and Methods
Application:
08/887,115 →
Nucleic Acids Encoding Human Nik Protein
Patent:
5,843,721 →
Application:
08/887,518 →
Ikk-B Proteins, Nucleic Acids and Methods
Patent:
5,851,812 →
Application:
08/890,853 →
Ikk-Alpha Proteins, Nucleic Acids and Methods
Patent:
6,235,512 →
Application:
08/890,854 →
Pentafluorobenzenesulfonamides and Analogs
Patent:
5,880,151 →
Application:
08/896,827 →
Nucleic Acids Encoding Murine UCP3 Genes
Patent:
5,846,779 →
Application:
08/937,466 →
Regulators of UCP3 Gene Expression
Patent:
5,849,581 →
Application:
08/948,277 →
Ikap Nucleic Acids
Patent:
5,891,719 →
Application:
08/971,244 →
Ikb Kinases
Patent:
5,776,717 →
Application:
08/971,937 →
Novel Protein-TRAF6
Patent:
5,767,244 →
Application:
08/975,405 →
Nuclear Hormone Receptor Drug Screens
Patent:
6,555,326 →
Application:
08/975,614 →
Interleukin-1 Receptor Accessory Proteins, Nucleic Acids and Methods
Patent:
6,280,955 →
Application:
08/991,944 →
Human Nik Protein
Patent:
5,844,073 →
Application:
09/023,321 →
Ikk-Alpha Proteins, Nucleic Acids and Methods
Patent:
6,235,513 →
Application:
09/023,324 →
High Throughput Screening Assays for Nucleic Acid Ligase Modulators
Patent:
6,153,384 →
Application:
09/025,979 →
Screening Method for Agents That Modulate Human Nik Activity
Patent:
5,854,003 →
Application:
09/032,475 →
Ikk-A Proteins, Nucleic Acids and Methods
Patent:
6,235,492 →
Application:
09/032,476 →
Suppressors of Death Domains
Patent:
6,437,113 →
Application:
09/035,676 →
High-Throughput Screening Assays for Modulators of Nucleic Acid Topoisomerases
Patent:
5,998,152 →
Application:
09/037,154 →
High Throughput Assay for Detection of Mrna in Cells
Application:
09/052,841 →
High-Throughput Screening Assays for Modulators of Primase Activity
Patent:
6,043,038 →
Application:
09/052,924 →
High Throughput in Vitro Screening Assays for Transcription Modulators
Patent:
6,183,956 →
Application:
09/052,995 →
High-Throughput Screening Assays for Modulators of STAT4 and STAT6 Activity
Patent:
6,207,391 →
Application:
09/053,003 →
Human Telomerase Gene Rna Interacting Protein Gene
Patent:
5,888,747 →
Application:
09/072,270 →
High-Throughput in Vitro Assays for Modulators of Peptidyl Transferase
Patent:
5,962,244 →
Application:
09/074,580 →
Ikk-Beta Proteins, Nucleic Acids and Methods
Patent:
5,939,302 →
Application:
09/099,124 →
Ikk-Bproteins Nucleic Acids and Methods
Patent:
5,916,760 →
Application:
09/099,125 →
Method of Identifying Agents That Modulate UCP2 Promoter Activity
Patent:
5,849,514 →
Application:
09/100,297 →
Ikk-Alpha Proteins Nucleic Acids and Methods
Patent:
6,479,266 →
Application:
09/109,986 →
Drug Screens for Regulators of the Expression of the Obese Gene
Patent:
6,432,654 →
Application:
09/114,552 →
Human Uncoupling Protein 2 (HUCP2): Compositions and Methods of Use
Application:
09/124,293 →
High-Throughput in Vitro Screening Assays for Modulators of Nucleic Acid Helicases
Patent:
6,569,619 →
Application:
09/124,312 →
Novel Retinal Nuclear Hormore Receptor
Application:
09/130,858 →
Rip: Novel Human Protein Involved in Tumor Necrosis Factor Signal Transduction
Patent:
6,211,337 →
Application:
09/132,118 →
Isolated Nucleic Acids Encoding CYP7 Promoter-Binding Factors
Patent:
5,958,697 →
Application:
09/132,619 →
IRAK3 Polypeptides and Methods
Patent:
6,262,228 →
Application:
09/135,232 →
Nuclear Hormone Receptor Drug Screens
Patent:
7,101,681 →
Application:
09/163,713 →
Assays for Identifying Agents Which Affect Regulators of UCP3 Gene Expression
Patent:
5,976,808 →
Application:
09/169,203 →
Murine UCP3 Polypeptides
Patent:
5,952,469 →
Application:
09/172,528 →
Human Retinoid-Like Orphan Receptor Gamma
Application:
09/178,358 →
CANDIDA ALBICANS mRNA 5'-TRIPHOSPHATASE (CET-1) POLYNUCLEOTIDES
Application:
09/213,678 →
Publication:
US 2002/0018774
Benzenesulfonamides and Benzamides as Therapeutic Agents
Patent:
6,191,170 →
Application:
09/226,703 →
Pentafluorobenzenesulfonamides and Analogs
Patent:
6,121,304 →
Application:
09/227,216 →
Ppar-Gamma Modulators
Patent:
6,200,995 →
Application:
09/234,327 →
Pyrimidine Derivatives
Patent:
6,200,977 →
Application:
09/249,641 →
TRAF2-Associated Protein Kinase and Assays
Patent:
5,981,250 →
Application:
09/252,571 →
CYP7 Promoter-Binding Factors
Patent:
6,027,901 →
Application:
09/282,803 →
Ikap Proteins and Methods
Patent:
6,172,195 →
Application:
09/286,891 →
Murine UCP3 Polypeptides
Patent:
6,025,469 →
Application:
09/318,199 →
Arylsulfonanilide Phosphates
Application:
09/336,062 →
Inhibitors of Stat Function
Patent:
6,426,331 →
Application:
09/349,208 →
High-Throughput Screening Assays for Modulators of Nucleic Acid Topoisomerases
Patent:
6,197,527 →
Application:
09/351,662 →
Arylsulfonanilide Derivatives
Patent:
6,153,585 →
Application:
09/353,976 →
Detection Method for Monitoring Beta Tubulin Isotype Specific Modification
Patent:
6,306,615 →
Application:
09/377,554 →
Ldl Receptor Gene Expression Promoters
Patent:
6,159,974 →
Application:
09/381,829 →
Arylsulfonanilide Ureas
Patent:
6,214,880 →
Application:
09/399,907 →
Sodd-Specific Antibodies and Methods
Patent:
6,110,690 →
Application:
09/416,213 →
Methods for Detecting Sodd Genes and Proteins
Patent:
6,413,728 →
Application:
09/416,214 →
Sodd Gene Expression in Cancer
Patent:
6,372,444 →
Application:
09/417,559 →
TRAF2-Associated Protein Kinase and Assays
Patent:
6,107,074 →
Application:
09/434,065 →
Methods of Assaying for Compounds That Inhibit Premature Translation Termination and Nonsense-Mediated Rna Decay
Patent:
6,458,538 →
Application:
09/461,508 →
Certain Polycyclic Compounds Useful as Tubulin-Binding Agents
Patent:
6,433,187 →
Application:
09/464,217 →
Fxr Receptor-Mediated Modulation of Cholesterol Metabolism
Patent:
6,465,258 →
Application:
09/478,948 →
Lxr Modulators
Patent:
6,906,069 →
Application:
09/479,315 →
UCP3 genes
Patent:
6,248,561 →
Application:
09/503,579 →
Recombinant Polynucleotides Encoding CYP7 Promoter-Binding Factors
Patent:
6,297,019 →
Application:
09/510,654 →
T2K Kinase Assays
Patent:
6,365,366 →
Application:
09/524,435 →
LXR modulators
Patent:
6,316,503 →
Application:
09/525,861 →
High-throughput screening assays for modulators of mitochondrial membrane potential
Application:
09/567,856 →
Publication:
US 2003/0170606
Arylsulfonanilide phosphates
Patent:
6,211,167 →
Application:
09/595,398 →
Pentafluorobenzenesulfonamides and analogs
Patent:
6,316,484 →
Application:
09/633,740 →
Arylsulfonanilide Derivates
Patent:
6,630,513 →
Application:
09/671,937 →
Modulators of Srebp Processing
Patent:
6,649,593 →
Application:
09/680,571 →
Inhibitors of Apoptosis
Patent:
6,821,736 →
Application:
09/689,366 →
Chandra: a Novel TH1-Specific Gene
Patent:
6,489,453 →
Application:
09/694,094 →
Nik-Knockout Mice
Patent:
6,822,138 →
Application:
09/706,236 →
Benzenesulfonamides and Benzamides as Therapeutic Agents
Patent:
6,583,161 →
Application:
09/736,040 →
Pyrimidine Derivatives
Ppargamma Modulators
Arylsulfonic Acid Salts of Pyrimidine-Based Antiviral
Rip: Novel Human Protein Involved in Tumor Necrosis Factor Signal Transduction
Irak-4: Compositions and Methods of Use
Antibacterial Agents
Battery charging controller and conditioning system for lead acid batteries
Application:
09/760,365 →
Publication:
US 2001/0019257
Arylsulfonanilide Phosphates
Therapeutic agent for hyperlipidemia
Application:
09/782,535 →
Publication:
US 2002/0119958
Arylsulfonanilide Ureas
Hydrazones and Analogs as Cholesterol Lowering Agents
High-Throughput Screening Assays for Modulators of STAT4 and STAT6 Activity
Solid Phase Synthesis of Lxr Ligands
NS5B Hcv Polymerase Inhibitors
Sitosterolemia Susceptibility Gene (Ssg): Compositions and Methods of Use
Combination Therapeutic Compositions and Method of Use
Pyrazole Antimicrobial Agents
Treatment of hypertriglyceridemia and other conditions using LXR modulators
Application:
09/848,990 →
Publication:
US 2002/0048572
Polypeptides and Nucleic Acids Associated with Cancer
Regulators of Apoptosis
IRAK3 Polynucleotides
Substituted Benzene Compounds as Antiproliferative and Cholesterol Lowering Agents
Human uncoupling protein-2 (hCP2): compositions and methods of use
Application:
09/884,814 →
Publication:
US 2002/0127600
Novel receptors
Application:
09/891,138 →
Publication:
US 2003/0083245
Quinolinyl and Benzothiazolyl Modulators
Detection method for monitoring beta tubulin isotype specific modification
Application:
09/934,025 →
Publication:
US 2002/0106705
Fxr Modulators
Pentafluorobenzenesulfonamides and Analogs
ABCG8 Vectors, Host Cells, and Method of Making
Novel receptors
Application:
09/990,940 →
Publication:
US 2003/0027252
Stat Modulators
Lometrexol combination therapy
Application:
10/010,740 →
Publication:
US 2002/0156023
Diagnosis and Treatment of Cancer Using Mammalian Pellino Polypeptides and Polynucleotides
Combination Therapy Using Pentafluorobenzenesulfonamides and Antineoplastic Agents
PRC17: an Amplified Cancer Gene
Application:
10/071,838 →
Publication:
US 2003/0044814
Amplified cancer gene hepsin
Application:
10/073,060 →
Publication:
US 2003/0049645
Methods of using pyrimidine-based antiviral agents
Application:
10/078,246 →
Publication:
US 2003/0130264
Novel receptors
Application:
10/094,417 →
Publication:
US 2003/0045685
Ppargamma Modulators
Fused Heterocyclic Compounds
Suppressors of Death Domains
Arylsulfonic Acid Salts of Pyrimidine-Based Antiviral Agents
Novel receptors
Application:
10/188,405 →
Publication:
US 2003/0082585
FXR receptor-mediated modulation of cholesterol metabolism
Application:
10/217,293 →
Publication:
US 2003/0003520
Methods of Assaying for Compounds That Inhibit Premature Translation Termination and Nonsense-Mediated Rna Decay
Inhibitors of Apoptosis
Ikk-Alpha Proteins, Nucleic Acids and Methods
Linked Biaryl Compounds
Polypeptides and nucleic acids associated with cancer
Application:
10/273,575 →
Publication:
US 2003/0108931
Quinolinyl and Benzothiazolyl Modulators
Application:
10/278,851 →
Publication:
US 2003/0171399
Fused Heterocyclic Compounds
Chandra: a TH1-Specific Protein
Pyrimidine Derivatives
Heterocyclic Arylsulfonamidobenzylic Compounds
Cell-Based Drug Screens for Regulators of Gene Expression
Combination therapeutic compositions and method of use
Application:
10/456,932 →
Publication:
US 2004/0259918
Bis-Aryl Thiazole Derivatives
Antiinflammation Agents
Piperidine Derivatives
Receptor Ligands and Methods of Modulating Receptors
Patent:
7,056,685 →
Application:
10/703,145 →
Fused Heterocyclic Compounds
Receptor Ligands and Methods of Modulating Receptors
Patent:
7,189,524 →
Application:
10/719,692 →
Quinolinyl and Benzothiazolyl Modulators
Asthma and Allergic Inflammation Modulators
Fxr Modulators
Gene amplification and overexpression in cancer
Application:
10/817,418 →
Publication:
US 2005/0004059
Gene amplification and overexpression in cancer
Application:
10/867,183 →
Publication:
US 2005/0026194
Antibacterial Agents
Asthma and allergic inflammation modulators
Application:
10/887,341 →
Publication:
US 2005/0038070
Fused Heterocyclic Compounds
Inhibitors of Apoptosis
Linked Biaryl Compounds
Salts and Polymorphs of a Potent Antidiabetic Compound
Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
Application:
10/977,364 →
Irak-4: Compositions and Methods of Use
Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
Application:
10/997,784 →
Publication:
US 2005/0250854
STAT modulators
Application:
11/014,344 →
Publication:
US 2005/0101540
Novel receptors
Application:
11/038,360 →
Publication:
US 2005/0170397
STAT6 Deficient Transgenic Animals
Application:
60/013,981 →
Pentafluorobenzenesulfonamides and Analogs
Application:
60/022,198 →
CYP7 Promoter-Binding Factors
Application:
60/067,708 →
Benzenesulfonamides and Benzamides as Therapeutic Agents
Application:
60/071,137 →
Ppargamma Modulators
Application:
60/073,042 →
Pyrimidine Derivatives
Application:
60/075,005 →
Antiviral Agents
Application:
60/075,224 →
Arylsulfonanilide Phosphates
Application:
60/090,681 →
Stat Binding Agents
Application:
60/092,098 →
Arylsulfonanilide Derivatives
Application:
60/093,570 →
Arylsulfonanilide Ureas
Application:
60/100,888 →
Tubulin-Binding Agents
Application:
60/112,613 →
Fxr Receptor-Mediated Modulation of Cholesterol Metabolism
Application:
60/115,249 →
Lxr Modulators
Application:
60/115,292 →
Methods of Modulating Uric Acid Levels
Application:
60/116,392 →
Lxr Modulators
Application:
60/124,525 →
Mitochondrial Membrane Potential Assays
Application:
60/133,268 →
Modulators of Srebp Processing
Application:
60/159,236 →
Chandra: a Novel TH1-Specific Gene
Application:
60/161,201 →
Antibacterial Agents
Application:
60/175,892 →
Arylsulfonic Acid Salts of Pyrimidine-Based Antiviral Agents
Application:
60/176,000 →
Irak-4 : Compositions and Methods of Use
Application:
60/176,395 →
Car Modulators: Screening and Treatment of Hypercholesterolemia
Application:
60/176,398 →
Hydrazones as cholesterol lowering agents
Application:
60/186,047 →
Hydrazone analogs as cholesterol lowering agents
Application:
60/186,249 →
Solid phase synthesis of LXR ligands
Application:
60/194,911 →
NS5B HCV polymerase inhibitors
Application:
60/194,912 →
Sitosterolemia susceptibility gene (SSG): compositions and methods of use
Application:
60/198,465 →
Treatment of hypertriglyceridemia and other conditions using LXR modulators
Application:
60/201,601 →
Combination therapeutic compositions and methods of use
Application:
60/201,613 →
Pyrazole antibacterial agents
Application:
60/201,988 →
Sitosterolemia susceptibility gene (ssg):compositions and methods of use
Application:
60/204,234 →
Novel G-protein coupled receptors
Application:
60/213,461 →
Quinolinyl and benzothiazolyl modulators of PPARgamma activity
Application:
60/214,810 →
FXR modulators
Application:
60/230,585 →
Combination therapy using pentafluorobenzenesulfonamides and antineoplastics agents
Application:
60/245,878 →
Stat modulators
Application:
60/246,876 →
ABCG5 and ABCG8: compositions and methods of use
Application:
60/252,235 →
Novel g-protein coupled receptors
Application:
60/252,841 →
ABCG5 and ABCG8: compositions and methods of use
Application:
60/253,645 →
Lometrexol combination therapy
Application:
60/254,030 →
TGR60: a novel oxytocin/vasopressin-related orphan GPCR
Application:
60/257,636 →
FXR modulators
Application:
60/258,092 →
Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
Application:
60/259,502 →
Lometrexol combination therapy
Application:
60/261,134 →
Novel receptor
Application:
60/261,377 →
PRC17: Amplified cancer gene
Application:
60/267,615 →
Amplified ovarian cancer gene hepsin
Application:
60/268,361 →
Methods of using pyrimidine-based antiviral agents
Application:
60/269,778 →
Novel receptors
Application:
60/276,649 →
TGR60: a novel oxytocin/vasopressin-related orphan GPCR
Application:
60/279,554 →
Novel receptor
Application:
60/280,696 →
Fused heterocyclic compounds
Application:
60/288,665 →
Bis-aryl thiazole derivatives
Application:
60/302,193 →
Novel receptors
Application:
60/302,800 →
Linked biaryl compounds
Application:
60/322,556 →
Linked biaryl compounds
Application:
60/335,434 →
Heterocyclic arylsulfonamidobenzylic compounds
Application:
60/353,496 →
Involvement of CTSZ gene in cancer
Application:
60/365,206 →
Linked biaryl compounds
Application:
60/378,627 →
Linked biaryl compounds
Application:
60/386,833 →
Piperidine derivatives
Application:
60/413,335 →
Receptor ligands and methods of modulating receptors
Application:
60/421,142 →
Antiinflammation agents
Application:
60/422,531 →
Receptor ligands and methods of modulating receptors
Application:
60/424,093 →
Fused heterocyclic compounds
Application:
60/424,456 →
Asthma and allergic inflammation modulators
Application:
60/435,366 →
Receptor ligands and methods of modulating receptors
Application:
60/444,153 →
Gene amplification and overexpression in cancer
Application:
60/462,702 →
Gene amplification and overexpression in cancer
Application:
60/479,833 →
Asthma and allergic inflammation modulators
Application:
60/485,978 →
Salts and polymorphs of a potent antidiabetic compound
Application:
60/508,470 →
Recreational swings and toddler attachments for swinging and spinning
Application:
60/523,463 →
Gene amplification and overexpression in cancer
Application:
60/524,050 →
Therapeutic modulation of PPARgamma activity
Application:
60/551,656 →
Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity
Application:
60/583,682 →
Furanopyrimidines
Application:
60/583,898 →
Substituted benzofused heterocycles
Application:
60/601,223 →
Bisaryl-sulfonamides
Application:
60/601,578 →
Related Assignments
(6)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 16, 2003
From: TULARIK INC.
To: CUMBRE INC.
Reel/Frame 014491/0871 →
Assignment of Assignor's Interest
Sep 16, 2003
From: TULARIK INC.
To: CUMBRE INC.
Reel/Frame 014497/0560 →
Merger
Jun 7, 2005
From: TULARIK INC.
To: ARROW ACQUISITION, LLC
Reel/Frame 016309/0003 →
Change of Name
Jun 7, 2005
From: ARROW ACQUISITION, LLC
To: AMGEN SF, LLC
Reel/Frame 016309/0812 →
Assignment of Assignor's Interest
May 13, 2009
From: CUMBRE PHARMACEUTICALS INC.
To: CUMBRE IP VENTURES, L.P.
Reel/Frame 022678/0001 →
Assignment of Assignor's Interest
Jan 15, 2015
From: CUMBRE IP VENTURES, L.P.
To: TENNOR THERAPEUTICS LIMITED
Reel/Frame 034721/0101 →